DONG Jintang, PhD, Chair Professor of School of Medicine, Southern University of Science and Technology. He received his BS degree in Biology from Nankai University in 1984 and PhD degree in Pathophysiology from Peking Union Medical College and Chinese Academy of Medical Sciences in 1989. He was a postdoctoral fellow in National Institutes of Health and Johns Hopkins University School of Medicine. And then assistant professor, associate professor of University of Virginia School of Medicine. And then associate professor, professor of Emory University School of Medicine. He joined SUSTech in 2018. He has finished a large number of research projects funded by national agencies. He is also the recipient of several awards. He has published more than 120 papers in international journals including Science, Nature Genetics and Nature Communications. He is an associate editor or on the editorial boards of multiple international journals, including Journal of Genetics and Genomics, The Prostate and Journal of Biological Chemistry. His research focuses on molecular pathogenesis of human cancer, particularly the oncogenes in prostate cancer progression. He has led the team to engage in basic molecular research of tumor development for more than 20 years, and has trained more than 30 doctors and postdocs.
Molecular basis of tumorigenesis and its application: professor Dong jintang's research group use a variety of research methods and tumor models, including genetics, biochemistry, cell biology, molecular biology and histopathology, to understand the biological mechanism of the initiation and progression of prostate cancer and to explore its application in tumor diagnosis and treatment.
Master and PhD students: Cancer Biology;
Undergraduate: Medical Genetics.
Academic and Professional Appointments
- 1989 – 10.1990: Assistant Investigator, Cancer Institute (Hospital), Chinese Academy of Medical Sciences, Beijing, China
- 1990 – 09.1994: Postdoctoral Visiting Fellow, Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, North Carolina
- 1994 – 09.1996: Postdoctoral Fellow, Johns Hopkins Oncology Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
- 1996 – 06.2001: Assistant Professor, Department of Pathology (Primary appointment), Department of Biochemistry and Molecular Genetics (secondary appointment), University of Virginia School of Medicine, Charlottesville, Virginia
- 2001 – 03. 2002: Associate Professor, Department of Pathology (Primary appointment), Department of Biochemistry and Molecular Genetics (secondary appointment), University of Virginia School of Medicine, Charlottesville, Virginia
- 2002 – 08.2007: Associate Professor (with tenure), Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia.
- 2007-08.2018：Professor (with tenure), Department of Hematology and Medical Oncology (Primary appointment), Department of Urology (secondary appointment), Emory University School of Medicine
- 2006 – 07.2018, Adjunct Professor, Department of Genetics and Cell Biology, Nankai University College of Life Sciences, Tianjin, China
- 2018-present, Chair professor, School of Medicine, Southern University of Science and Technology
- 1984, B.Sc. in Biology, Nankai University, Tianjin, China. Thesis advisor: Prof. Yuhe Li
- 1989, Ph.D. in Pathophysiology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. Mentor: Dr. Xian-Mao Luo
- Postdoctoral Fellow in Molecular Cancer Biology, Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina. Mentor: Dr. J. Carl Barrett. 10.1990 – 09.1994
- Postdoctoral Fellow in prostate cancer biology, the Oncology Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. Mentor: Dr. John T. Isaacs. 10.1994 – 09.1996
Published and Accepted Research Articles (clinical, basic science, other) in Refereed Journals (excluding 8 publications in Chinese from 1988 to 1992):
(1) Annab LA, Dong JT, Futreal PA, Satoh H, Oshimura M, Barrett JC (1992) Growth and transformation suppressor genes for BHK Syrian hamster cells on human chromosomes 1 and 11. Mol Carcinog 6:280-288.
(2) Ichikawa T, Ichikawa Y, Dong JT, Hawkins AL, Griffin CA, Isaacs WB, Oshimura M, Barrett JC, Isaacs JT (1992) Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11. Cancer Res 52:3486-3490.
(3) Dong JT, Luo XM (1993) Arsenic-induced DNA-strand breaks associated with DNA-protein crosslinks in human fetal lung fibroblasts. Mutat Res 302:97-102.
(4) Satoh H, Lamb PW, Dong JT, Everitt J, Boreiko C, Oshimura M, Barrett JC (1993) Suppression of tumorigenicity of A549 lung adenocarcinoma cells by human chromosomes 3 and 11 introduced via microcell-mediated chromosome transfer. Mol Carcinog 7:157-164.
(5) Dong JT, Luo XM (1994) Effects of arsenic on DNA damage and repair in human fetal lung fibroblasts. Mutat Res 315:11-15.
(6) Rinker-Schaeffer CW, Hawkins AL, Ru N, Dong JT, Stoica G, Griffin CA, Ichikawa T, Barrett JC, Isaacs JT (1994) Differential suppression of mammary and prostate cancer metastasis by human chromosomes 17 and 11. Cancer Res 54:6249-6256.
(7) Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barrett JC (1995) KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 268:884-886.
(8) Dong JT, Zhou CN, Luo XM (1995) Induction of preneoplastic lesions by sodium arsenite in human fetal respiratory epithelia in organ culture. Environ Res 68:39-43.
(9) Dong JT, Suzuki H, Pin SS, Bova GS, Schalken JA, Isaacs WB, Barrett JC, Isaacs JT (1996) Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 56:4387-4390.
(10) Dong JT, Isaacs WB, Barrett JC, Isaacs JT (1997) Genomic organization of the human KAI1 metastasis-suppressor gene. Genomics 41:25-32.
(11) Gao AC, Lou W, Dong JT, Isaacs JT (1997) CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res 57:846-849.
(12) Kawana Y, Komiya A, Ueda T, Nihei N, Kuramochi H, Suzuki H, Yatani R, Imai T, Dong JT, Imai T, Yoshie O, Barrett JC, Isaacs JT, Shimazaki J, Ito H, Ichikawa T (1997) Location of the KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer. Prostate 32:205-213.
(13) Dong JT, Sipe TW, Hyytinen ER, Li CL, Heise C, McClintock DE, Grant CD, Chung LW, Frierson HF, Jr. (1998) PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Oncogene 17:1979-1982.
(14) Suzuki H, Dong JT, Gao AC, Barrett JC, Isaacs JT (1998) Identification of the rat homologue of KAI1 and its expression in Dunning rat prostate cancers. Prostate 37:253-260.
(15) Hyytinen ER, Frierson HF, Boyd JC, Chung LWK, Dong JT (1999) Three distinct regions of allelic loss at 13q14, 13q21-22, and 13q33 in prostate cancer. Gene Chromosome Cancer 25:108-114.
(16) Hyytinen ER, Frierson HF Jr, Sipe TW, Li CL, Degeorges A, Sikes RA, Chung LW, Dong JT (1999) Loss of heterozygosity and lack of mutations of the XPG/ERCC5 DNA repair gene at 13q33 in prostate cancer. Prostate. 41(3): 190-195.
(17) Lou W, Krill D, Dhir R, Becich M, Dong JT, Frierson HF, Isaacs WB, Isaacs JT, Gao AC (1999) Methylation of the CD44 metastatic suppressor gene in human prostate cancer. Cancer Res, 59:2329-2331.
(18) Dong JT, Chen C, Stultz BG, Isaacs JT, Frierson HF, Jr. (2000) Deletion at 13q21 is associated with aggressive prostate cancers. Cancer Res 60:3880-3883.
(19) Liu FS, Dong JT, Chen JT, Hsieh YT, Ho ESC, Hung MJ (2000) Frequent down-regulation and lack of mutation of the KAI1 metastasis suppressor gene in epithelial ovarian carcinoma. Gynecol Oncol 78:10-15.
(20) Chen C, Brabham W, Stultz BG, Frierson HFJ, Barrett JC, Sawyers CL, Isaacs JT, and Dong JT (2001) Defining a common region of deletion at 13q21 in human cancers. Genes Chromosomes Cancer 31:333-344.
(21) Chen C, Frierson HFJ, Haggerty PF, Theodorescu D, Gregory CW, Dong JT (2001) An 800 kb region of deletion at 13q14 in human prostate and other carcinomas. Genomics 77:135-144.
(22) Dong JT, Li CL, Sipe TW, Frierson HF, Jr. (2001) Mutation of PTEN/MMAC1 in primary prostate cancers from Chinese patients. Clin Cancer Res 7:304-308.
(23) Dong JT, Boyd JC, Frierson HF, Jr. (2001) Loss of heterozygosity at 13q14 and 13q21 in high grade prostate cancer. Prostate 49:166-171.
(24) Liu FS, Chen JT, Dong JT, Hsieh YT, Lin AJ, Ho ESC, Hung MJ, and Lu CH (2001) KAI1 metastasis suppressor gene is frequently down regulated in cervical carcinoma. Am J Pathol 159:1629-1634.
(25) Hyytinen ER, Saduut R, Chen C, Lindsay Paull L, Koivisto PA, Vessella RL, Frierson HF, Dong JT (2002) Defining the Region(s) of Deletion at 6q16-q22 in Human Prostate Cancer. Genes Chromosomes Cancer 34:306-312.
(26) Chen C, Bhalala HV, Qiao H, and Dong JT (2002) A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer. Oncogene 21:6567-6572.
(27) Liu FS, Chen JT, Dong JT, Hsieh YT, Lin AJ, Ho ES, Hung MJ & Lu CH (2002) Author's Reply : KAI1 metastasis suppresor gene is frequently down-regulated in cervical carcinoma. Am J Pathol160:1542-1543.
(28) Chen C, Hyytinen ER, Sun X, Helin HJ, Koivisto PA, Frierson HF, Vessella RL, and Dong JT (2003) Deletion, mutation, and loss of expression of the KLF6 tumor suppressor gene in a subset of prostate cancer. Am J Pathol 162:1349-1354.
(29) Chen C, Bhalala HV, Vessella RL, and Dong JT (2003) KLF5 is frequently deleted and down-regulated but rarely mutated in prostate cancer. Prostate 55:81-88.
(30) Liu FS, Dong JT, Chen JT, Hsieh YT, Lin AJ, Ho ESC, Hung MJ, and Lu CH (2003) KAI1 metastasis suppressor protein is down-regulated during the progression of human endometrial cancer. Clin Cancer Res 9:1393-1398.
(31) Gao AC, Lou W, Dong JT, Barrett JC, Danielpour D, and Isaacs JT (2003) Defining regulatory elements in the human KAI1 (CD 82) metastasis suppressor gene. Prostate 57:256-260.
(32) Chen C, Zhou Y, Zhou Z, Sun X, Otto KB, Uht RM, and Dong JT (2004) Regulation of KLF5 involves the Sp1 transcription factor in human epithelial cells. Gene 330:133-142.
(33) Wang R, Xu J, Saramaki O, Visakorpi T, Sutherland WM, Zhou J, Sen B, Lim SD, Mabjeesh N, Amin M, Dong JT, Petros JA, Nelson PS, Marshall FF, Zhau HE, and Chung LW (2004) PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer. Cancer Res 64:1589-1594.
(34) Koivisto PA, Zhang X, Sallinen SL, Sallinen P, Helin HJ, Dong JT, Van Meir EG, Haapasalo H, and Hyytinen ER (2004) Absence of KLF6 gene mutations in human astrocytic tumors and cell lines. Int J Cancer111: 642-643.
(35) Chen C, Sun X, Ran Q, Wilkinson KD, Murphy TJ, Simons JW, and Dong JT (2005) Ubiquitin-proteasome degradation of KLF5 transcription factor in cancer and untransformed epithelial cells. Oncogene 24:3319-3327, 2005.
(36) Sun X, Frierson HF, Chen C, Li C, Ran Q, Otto KB, Cantarel BL, Vessella RL, Gao AC, Petros J, Miura Y, Simons JW, and Dong JT (2005) Frequent somatic mutations of the ATBF1 transcription factor in human prostate cancer. Nat Genet37: 407-412.
(37) Guo GM, Huang XP, Dong JT, Caia Y, Xu X, Han YL, Wu M, Zhan QM, and Wang MR (2005) A novel region of deletion on 13q33-q34 in esophageal squamous cell carcinoma. Oncol Rep 14:1639-46.
(38) Chen C, Guo P, Sun X, Dong XY, Sethi P, Cheng X, Zhou J, Ling J, Simons JW, Lingrel JB, and Dong JT (2005) KLF5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells. J Biol Chem 280:41553-41561.
(39) Chen C, Benjamin MS, Sun X, Otto KB, Guo P, Dong XY, Bao Y, Zhou Z, Cheng X, Simons JW &Dong JT (2006). KLF5 promotes cell proliferation and tumorigenesis through gene regulation in the TSU-Pr1 human bladder cancer cell line. Int J Cancer 118:1346-1355.
(40) Sun X, Chen C, Vessella RL, and Dong JT (2006) Microsatellite instability and mismatch repair target gene mutations in cell lines and xenografts of prostate cancer. Prostate 66:660-666.
(41) Zhu N, Gu L, Findley HW, Chen C, Dong JT, Yang L, and Zhou M (2006) KLF5 interacts with P53 in regulating survivin expression in acute lymphoblastic leukemia. J Biol Chem 281(21):14711-14718.
(42) Liu M, Aneja R, Liu C, Sun L, Gao J, Wang H, Dong JT, Sarli V, Giannis A, Joshi HC, and Zhou J (2006) Inhibition of the mitotic kinesin Eg5 upregulates Hsp70 through the PI3K/Akt pathway in multiple myeloma cells. J Biol Chem 281(26):18090-18097.
(43) Zhong D, Morikawa A, Guo L, Colpaert C, Xiong L, Nassar A, Chen C, Lamb N, Dong JT, and Zhou W (2006) Homozygous deletion of SMAD4 in breast cancer cell lines and invasive ductal carcinomas. Cancer Biol Ther 5(6):601-7.
(44) Dong XY, Chen C, Sun X, Guo P, Vessella RL, Wang RX, Chung LW, Zhou W, and Dong JT (2006) FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting AR signaling in prostate cancer. Cancer Res 66:6998-7006.
(45) Wu YP, Yang YL, Yang GZ, Wang XY, Luo ML, Zhang Y, Feng YB, Xu X, Han YL, Cai Y, Zhan QM, Wu M, Dong JT, and Wang MR (2006) Identification of chromosome aberrations in esophageal cancer cell line KYSE180 by multicolor fluorescence in situ hybridization. Cancer Genet Cytogenet 170:102-107.
(46) Chen C, Sun X, Guo P, Dong XY, Sethi P, Zhou W, Zhou Z, Petros J, Frierson HF, Vessella RL, Atfi A, and Dong JT (2007) Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer. Oncogene 26: 2386-2394.
(47) Sun X, Zhou Y, Otto KB, Wang M, Chen C, Zhou W, Subramanian K, Vertino PM, and Dong JT (2007) Infrequent mutation of ATBF1 in human breast cancer. J Cancer Res Clin Oncol 133:103-5.
(48) Chen C, Zhou Z, Guo P and Dong JT. Proteasomal degradation of the KLF5 transcription factor through a ubiquitin independent pathway. FEBS Lett 581:1124-1130, 2007.
(49) Chen C, Zhou Z, Ross JS, Zhou W, and Dong JT (2007) The amplified WWP1 gene is a potential molecular target in breast cancer. Int J Cancer 121:80-87, 2007.
(50) Yang YL, Chu JY, Luo ML, Wu YP, Zhang Y, Feng YB, Shi ZZ, Xu X, Han YL, Cai Y, Dong JT, Zhan QM, Wu M, and Wang MR (2008) Amplification of PRKCI, located in 3q26, is associated with lymph node metastasis in esophageal squamous cell carcinoma. Genes Chromosomes Cancer 47:127-136.
(51) He S, Guo GM, Liu FX, Huang XP, Xu X, Cai Y, Han YL, Zhan QM, Wu M, Dong JT, Wang GQ, and Wang MR (2008) Molecular analysis in combination with iodine staining may contribute to the risk prediction of esophageal squamous cell carcinoma. J Cancer Res Clin Oncol134:307-315.
(52) Dong XY, Rodriguez C, Guo P, Sun X, Talbot JT, Zhou W, Petros J, Li Q, Vessella RL, Kibel AS, Stevens VL, Calle EE, and Dong JT (2008) SnoRNA U50 is a candidate tumor suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. Hum Mol Genet17:1031-142.
(53) Sun L, Li D, Dong X, Yu H, Dong JT, Zhang C, Lu X, and Zhou J (2008) Small-molecule inhibition of Aurora kinases triggers spindle checkpoint-independent apoptosis in cancer cells. BiochemPharmacol. 75:1027-1034.
(54) Gao J, Huo L, Sun X, Liu M, Li D, Dong JT, and Zhou J (2008) The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration. J Biol Chem283:8802-8809.
(55) Sun L, Gao J, Dong X, Liu M, Shi X, Liu C, Dong JT, Lu X, Li D, and Zhou J (2008) EB1 promotes Aurora-B kinase activity through blocking its inactivation by protein phosphatase 2A. Proc Natl Acad Sci U S A105:7153-7158.
(56) Guo L, Zhong D, Lau S, Liu X, Dong XY, Sun X, Yang VW, Vertino PM, Moreno CS, Varma V, Dong JT, and Zhou W (2008) Sox7 Is an independent checkpoint for beta-catenin function in prostate and colon epithelial cells. Mol Cancer Res 6:1421-30.
(57) Liu M, Aneja R, Sun X, Xie S, Wang H, Wu X, Dong JT, Li M, Joshi HC, and Zhou J (2008) Parkin regulates Eg5 expression by Hsp70 ubiquitination-dependent inactivation of the c-Jun NH2-terminal kinase. J Biol Chem283:35783-8.
(58) Chen L, Zhu Z, Sun X, Dong XY, Wei J, Gu F, Sun YL, Zhou J, Dong JT, and Fu L (2009) Down-regulation of tumor suppressor gene FEZ1/LZTS1 in breast carcinoma involves promoter methylation and associates with metastasis. Breast Cancer Res Tt 116:471-8.
(59) Guo P, Dong XY, Zhang X, Zhao KW, Sun X, Li Q, and Dong JT (2009) Pro-proliferative factor KLF5 becomes anti-proliferative in epithelial homeostasis upon signaling-mediated modification. J Biol Chem284:6071-8..
(60) Wang H, Liu B, Zhang C, Peng G, Liu M, Li D, Gu F, Chen Q, Dong JT, Fu L, and Zhou J (2009) Parkin regulates paclitaxel sensitivity in breast cancer via a microtubule-dependent mechanism. J Pathol218:76-85.
(61) Wang XC, Wu YP, Ye B, Lin DC, Feng YB, Zhang ZQ, Xu X, Han YL, Cai Y, Dong JT, Zhan QM, Wu M, and Wang MR (2009) Suppression of anoikis by SKP2 amplification and overexpression promotes metastasis of esophageal squamous cell carcinoma. Mol Cancer Res 7:12-22.
(62) Liu R, Zheng HQ, Zhou Z, Dong JT, and Chen C (2009) KLF5 promotes breast cell survival partially through FGF-BPpERK-mediated MKP-1 protein phosphorylation and stabilization. J Biol Chem284:16791-8.
(63) Guo P, Zhao KW, Dong XY, Sun X, and Dong JT (2009) Acetylation of KLF5 alters the assembly of P15 transcription factors in TGFbeta-mediated induction in epithelial cells. J Biol Chem284:18184-93.
(64) Dong XY, Guo P, Boyd J, Sun X, Li Q, Zhou W, and Dong JT (2009) Implication of snoRNA U50 in human breast cancer. J Genet Genomics36:447-54.
(65) Zheng HQ, Zhou Z, Huang J, Chaudhury L, Dong JT, and Chen C (2009) Krüpple-like factor 5 promotes breast cell proliferation partially through upregulating the transcription of fibroblast growth factor-binding protein 1. Oncogene28:3702-3713.
(66) Guo P, Dong XY, Zhao KW, Sun X, Li Q, and Dong JT (2009) Opposing effects of KLF5 on the transcription of Myc in epithelial proliferation in the context of TGFbeta. J Biol Chem284:28243-28252.
(67) Guo P, Dong XY, Zhao KW, Sun X, Li Q, and Dong JT (2010) Estrogen-induced interaction between KLF5 and estrogen receptor (ER) suppresses the function of ER in ER-positive breast cancer cells. Int J Cancer 126:81-89.
(68) Dong X, Liu F, Sun L, Liu M, Li D, Su D, Zhu Z, Dong JT, Fu L, and Zhou J (2010) Oncogenic function of microtubule end-binding protein 1 in breast cancer. J Pathol 220:361-369.
(69) Dong XY, Sun X, Guo P, Li Q, Sasahara M, Ishii Y, and Dong JT (2010) ATBF1 inhibits ER function by selectively competing with AIB1 for binding to ER in ER-positive breast cancer cells. J Biol Chem 285:32801-32809.
(70) Wang XX, Fu L, Li X, Wu X, Zhu Z, Fu L, and Dong JT (2011) Somatic mutations of the mixed-lineage leukemia 3 (MLL3) gene in primary breast cancers. Path Onc Res17:429-433.
(71) Zhao KW, Sikriwal D, Dong X, Guo P, Sun X &Dong JT (2011). Estrogen causes degradation of KLF5 by inducing the E3 ubiquitin ligase EFP in ER-positive breast cancer cells. Biochem J437:323-333.
(72) Dong XY, Guo P, Sun X, Li Q, and Dong JT (2011) Estrogen upregulates ATBF1 transcription but causes its protein degradation in ER-positive breast cancer cells. J Biol Chem 286:13879-13890.
(73) Wang XX, Zhu Z, Su D, Lei T, Wu X, Fan Y, Li X, Zhao J, Fu L, Dong JT, and Fu L (2011) Downregulation of LZTS1 is associated with poor prognosis, increased cell motility and invasion, and EMT characteristics in human breast carcinoma. Human Pathology42:1410-1419.
(74) Zhang Z, Zhang B, Li W, Fu L, Fu L, Zhu Z, and Dong JT (2011) Epigenetic silencing of miR-203 upregulates SNAI2 and contributes to the invasiveness of malignant breast cancer cells. Genes Cancer 2:782-791.
(75) Su D, Fu X, Fan S, Wu X, Wang XX, Fu L, Dong XY, Ni JJ, Zhu Z, and Dong JT (2012) Role of ERRF, a novel ER-related nuclear factor, in the growth control of ER-positive human breast cancer cells. Am J Pathol 180:1189-201.
(76) Wu X, Zhu Z, Li W, Fu X, Su D, Fu L, Zhang Z, Luo A, Sun X, and Dong JT (2012) Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer. Breast Cancer Res 14:R73.
(77) Dong XY, Fu X, Fan S, Guo P, Su D, and Dong JT (2012) Oestrogen causes ATBF1 protein degradation through the oestrogen-responsive E3 ubiquitin ligase EFP. Biochem J 444:581-590.
(78) Sun X, Fu X, Li J, Xing C, Martin D, Zhang H, and Dong JT (2012) Heterozygous deletion of Atbf1 by the Cre-loxP system in mice causes preweaning mortality. Genesis50(11):819-827.
(79) Hao JJ, Shi ZZ, Zhao ZX, Zhang Y, Gong T, Li CX, Zhan T, Cai Y, Dong JT, Fu SB, Zhan QM, and Wang MR (2012) Characterization of genetic rearrangements in esophageal squamous carcinoma cell lines by a combination of M-FISH and array-CGH: further confirmation of some split genomic regions in primary tumors. BMC Cancer 12:367.
(80) Li M, Fu X, Ma G, Sun X, Dong XY, Nagy T, Xing C, Li J, and Dong JT (2012) Atbf1 regulates pubertal mammary gland development likely by inhibiting the pro-proliferative function of estrogen-ER signaling. PLoS ONE7(12):e51283.
(81) Li M, Zhao D, Ma G, Zhang B, Fu X, Zhu Z, Fu L, Sun X, and Dong JT (2012) Upregulation of ATBF1 by progesterone-PR signaling and its functional implication in mammary epithelial cells. BiochemBiophys Res Commun 430(1):358-363.
(82) Sun X, Li J, Sica G, Fan SQ, Wang Y, Chen Z, Muller S, Chen ZG, Fu X, Dong XY, Guo P, Shin DM, and Dong JT (2012) Interruption of nuclear localization of ATBF1 during the histopathologic progression of head and neck squamous cell carcinoma.. Head Neck35:1007-1014, 2013.
(83) Hao JJ, Gong T, Zhang Y, Shi ZZ, Xu X, Dong JT, Zhan QM, Fu SB, and Wang MR (2013) Characterization of gene rearrangements resulted from genomic structural aberrations in human esophageal squamous cell carcinoma KYSE150 cells. Gene 513:196-201.
(84) Xing C, Fu X, Sun X, Guo P, Li M, and Dong JT (2013) Different expression patterns and functions of acetylated and unacetylated Klf5 in the proliferation and differentiation of prostatic epithelial cells. PLoS ONE 8:e65538.
(85) Xing C, Fu X, Sun X, and Dong JT (2013) Lack of an additive effect between the deletions of Klf5 and Nkx3-1 in mouse prostatic tumorigenesis. J Genet Genomics 40:315-318.
(86) Zhang B, Zhang Z, Xia S, Xing C, Ci X, Li X, Zhao R, Tian S, Ma G, Zhu Z, Fu L, and Dong JT (2013) KLF5 activates miR-200 transcription to maintain epithelial characteristics and prevent induced EMT in epithelial cells. Mol Cell Biol33：4919-4935.
(87) Martin-Garrido A, Williams HC, Lee M, Seidel-Rogol B, Ci X, Dong JT, Lassegue B, Martin AS, and Griendling KK (2013) Transforming growth factor beta inhibits platelet derived growth factor-induced vascular smooth muscle cell proliferation via Akt-independent, smad-mediated cyclin D1 downregulation. PLoS ONE 8:e79657.
(88) Sun X, Li J, Dong FN, and Dong JT (2014) Characterization of nuclear localization and SUMOylation of the ATBF1 transcription factor in epithelial cells. PLoS ONE 9:e92746.
(89) Zhang Z, Zhu Z, Zhang B, Li W, Li X, Wu X, Wang L, Fu L, Fu L, and Dong JT (2014) Frequent mutation of rs13281615 and its association with PVT1 expression and cell proliferation in breast cancer. J Genet Genom 41:187-195.
(90) Li X, Zhang B, Wu Q, Ci X, Zhao R, Zhang Z, Xia S, Su D, Chen J, Ma G, Fu L, and Dong JT (2014) Interruption of KLF5 acetylation converts its function from tumor suppressor to tumor promoter in prostate cancer cells. Int J Cancer 136(3):536-546.
(91) Sun X, Fu X, Li J, Xing C, Frierson HF, Wu H, Ding X, Ju T, Cummings RD, Dong JT (2014)Deletion of atbf1/zfhx3 in mouse prostate causes neoplastic lesions, likely by attenuation of membrane and secretory proteins and multiple signaling pathways. Neoplasia. 16(5):377-89.
(92) Sakata N, Kaneko S, Ikeno S, Yutaka M, Nakabayashi H, Dong XY, Dong JT, Tamaki T, Nakano N, and Itoh S (2014) TGFbeta signaling cooperates with AT motif-binding factor-1 (ATBF1) for repression of the alpha-fetoprotein promote. J Signal Transduct 2014:970346 (11 pages).
(93) Xing C, Ci X, Sun X, Fu X, Zhang Z, Dong EN, Hao ZZ, and Dong JT (2014) Klf5 deletion promotes Pten deletion-initiated luminal type mouse prostate tumors via multiple oncogenic signaling pathways. Neoplasia 16(11):883-899.
(94) Ci X, Xing C, Zhang B, Zhang Z, Ni JJ, Zhou W, and Dong JT (2015) KLF5 inhibits angiogenesis in PTEN-deficient prostate cancer by attenuating AKT activation and subsequent HIF1alpha accumulation. Mol Cancer 14:91(15 pages).
(95) Zhao H, Gao A, Zhang Z, Tian R, Luo A, Li M, Zhao D, Fu L, Fu L, Dong JT, and Zhu Z (2015) Genetic analysis and preliminary function study of miR-423 in breast cancer. Tumour Biol.,36:4763-4771.
(96) Sun X, Xing C, Fu X, Li J, Zhang B, Frierson HFJ, and Dong JT (2015) Additive effect of Zfhx3/Atbf1 and Pten deletion on mouse prostatic tumorigenesis. J Genet Genomics42(7):373-82.
(97) Zhang B, Zhao R, He Y, Fu X, Fu L, Zhu Z, Fu L, and Dong JT (2015) Micro RNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR. Oncotarget 7(5):5702-5714.
(98) Luo A, Su D, Zhang X, Qi L, Fu L, and Dong JT (2016) Estrogen-estrogen receptor signaling suppresses the transcription of ERRF in breast cancer cells. J Genet Genomics 43:565-567.
(99) Zhao D, Ma G, Zhang X, He Y, Li M, Han X, Fu L, Dong XY, Nagy T, Zhao Q, Fu L, and Dong JT (2016) Zinc finger homeodomain factor Zfhx3 is essential for mammary lactogenic differentiation by maintaining prolactin signaling activity. J Biol Chem 291:12809-12820.
(100) Luo A, Zhang X, Fu L, Zhu Z, and Dong JT (2016) Zinc finger factor ZNF121 is a MYC-interacting protein functionally affecting MYC and cell proliferation in epithelial cells. J Genet Genomics 43:677-685.
(101) Qi L, Zhang B, Zhang S, Ci X, Wu Q, Ma G, Luo A, Fu L, King JL, Nahta R, and Dong JT (2017) ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression. Oncotarget8:36054-36066.
(102) Xia S, Lin R, Jin L, Zhao L, Kang HB, Pan Y, Liu S, Qian G, Qian Z, Konstantakou E, Zhang B, Dong JT, Chung YR, Abdel-Wahab O, Merghoub T, Zhou L, Kudchadkar RR, Lawson DH, Khoury HJ, Khuri FR, Boise LH, Lonial S, Lee BH, Pollack BP, Arbiser JL, Fan J, Lei QY, and Chen J (2017) Prevention of dietary-fat-fueled ketogenesis attenuates BRAF V600E tumor growth. Cell Metab 25:358-373.
(103) Tian X, Tao F, Zhang B, Dong JT, and Zhang Z (2018) The miR-203/SNAI2 axis regulates prostate tumor growth, migration, angiogenesis and stemness potentially by modulating GSK-3beta/beta-CATENIN signal pathway. IUBMB Life 70:224-236.
(104) Tao R, Zhang B, Li Y, King JL, Tian R, Xia S, Schiavon CR, and Dong JT (2018) HDAC-mediated deacetylation of KLF5 associates with its proteasomal degradation. BiochemBiophys Res Commun 500:777-782.
(105) Gao A, Sun T, Ma G, Cao J, Hu Q, Chen L, Wang Y, Wang Q, Sun J, Wu R, Wu Q, Zhou J, Liu L, Hu J*, Dong JT*, and Zhu Z* (2018) LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERalpha pathway. Nat Commun 9(1): in press.(* Co-corresponding author)
(106) King JL, Zhang B, Li Y, Li KP, Ni JJ, Saavedra HI, and Dong JT (2018) TTK promotes mesenchymal signaling via multiple mechanisms in triple negative breast cancer. Oncogenesis 7:69.
(107) Wu Q, Fu C, Li M, Li J, Li Z, Qi L, Ci X, Ma G, Gao A, Fu X, Jun A, Na A, Liu M, Li Y, King JL, Fu L, Zhang B, &Dong JT(2018) CINP is a novel cofactor of KLF5 required for its role in the promotion of cell proliferation, survival, and tumor growth. Int. J. Cancer, in press.
(108) Luo A, Zhang K, Zhao Y, Zhu Z, Fu L, and Dong JT (2018) ZNF121 interacts with ZBRK1 and BRCA1 to regulate their target genes in mammary epithelial cells. FEBS Open Bio, In press.
(109) Hu Q, Zhang B, Chen R, Fu C, A J, Fu X, Li J, Fu L, Zhang Z, Dong JT(2019)ZFHX3 is indispensable for ERβ to inhibit cell proliferation via MYC downregulation in prostate cancer cells. Oncogenesis 8(4):28.